Top 5 CRISPR Stocks To Invest In

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 50

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of medicines for eye disorders, allergies, inflammatory diseases, cardiovascular issues, infectious diseases, and rare diseases. It is one of the top gene editing stocks to invest in. 

On October 3, 2023, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia announced an extended research partnership aimed at developing CRISPR-based therapies for treating neurological and muscular diseases. The collaboration leverages Intellia’s advanced genome editing platform, including its exclusive Nme2Cas9 technology, in conjunction with Regeneron’s proprietary antibody-targeted viral vector delivery technologies. Together, the two companies aim to advance in vivo programs targeting neurological and muscular diseases beyond the liver.

According to Insider Monkey’s third quarter database, 50 hedge funds were bullish on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), compared to 56 funds in the prior quarter. D E Shaw is the leading stakeholder of the company, with 370,421 shares worth $304.8 million. 

Bronte Capital Amalthea Fund made the following comment about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2023 investor letter:

“In the last quarterly letter, we discussed the problems in our long book. These were:

1. a) companies that sell technical products to improve the conversion of grain into meat (such as animal genetics and feed additives), and
2. b) Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), which had received a “Complete Response Letter” (an FDA rejection) for their new longer-lasting wet age-related macular degeneration drug.

The first of these problems has persisted. Grain prices remain high relative to meat prices and the stocks in question have followed their quality European peers down. The two losers in this sector are Genus and DSM-Firmenich…” (Click here to read the full text)